ID   KRIT1_HUMAN             Reviewed;         736 AA.
AC   O00522; A6NNU0; O43894; Q506L6; Q6U276; Q75N19; Q9H180; Q9H264; Q9HAX5;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 2.
DT   28-JUN-2023, entry version 205.
DE   RecName: Full=Krev interaction trapped protein 1;
DE            Short=Krev interaction trapped 1;
DE   AltName: Full=Cerebral cavernous malformations 1 protein;
GN   Name=KRIT1; Synonyms=CCM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2),
RP   TISSUE SPECIFICITY, AND INTERACTION WITH RAP1A.
RC   TISSUE=Kidney, and Mammary cancer;
RX   PubMed=9285558; DOI=10.1038/sj.onc.1201268;
RA   Serebriiskii I., Estojak J., Sonoda G., Testa J.R., Golemis E.A.;
RT   "Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing
RT   protein encoded by a gene mapping to 7q21-22.";
RL   Oncogene 15:1043-1049(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11161791; DOI=10.1006/geno.2000.6410;
RA   Zhang J., Clatterbuck R.E., Rigamonti D., Dietz H.C.;
RT   "Cloning of the murine Krit1 cDNA reveals novel mammalian 5' coding
RT   exons.";
RL   Genomics 70:392-395(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING.
RX   PubMed=11161805; DOI=10.1006/geno.2000.6426;
RA   Sahoo T., Goenaga-Diaz E., Serebriiskii I.G., Thomas J.W., Kotova E.,
RA   Cuellar J.G., Peloquin J.M., Golemis E., Beitinjaneh F., Green E.D.,
RA   Johnson E.W., Marchuk D.A.;
RT   "Computational and experimental analyses reveal previously undetected
RT   coding exons of the KRIT1 (CCM1) gene.";
RL   Genomics 71:123-126(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING, AND VARIANTS
RP   CCM1 SER-97 AND GLU-569.
RX   PubMed=12172908; DOI=10.1007/s00401-002-0552-6;
RA   Kehrer-Sawatzki H., Wilda M., Braun V.M., Richter H.-P., Hameister H.;
RT   "Mutation and expression analysis of the KRIT1 gene associated with
RT   cerebral cavernous malformations (CCM1).";
RL   Acta Neuropathol. 104:231-240(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Ferrera L., Marini V., Dorcaratto A., Pigatto F., Alberti F., Forni M.,
RA   Cama A., Viale G., Origone P., Mareni C., Garre' C.;
RT   "Four novel and three known KRIT1 mutations in CCM Italian patients:
RT   Characterization at mRNA and protein level.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-243, AND ALTERNATIVE SPLICING.
RX   PubMed=11342228; DOI=10.1016/s0167-4781(00)00303-1;
RA   Eerola I., McIntyre B., Vikkula M.;
RT   "Identification of eight novel 5`-exons in cerebral capillary malformation
RT   gene-1 (CCM1) encoding KRIT1.";
RL   Biochim. Biophys. Acta 1517:464-467(2001).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 244-281.
RA   Marini V., Ferrera L., Dorcaratto A., Forni M., Capra V., Origone P.,
RA   Mareni C., Garre' C.;
RT   "Six novel and three known KRIT1 mutations in CCM patients:
RT   characterization at mRNA level.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   FUNCTION, INTERACTION WITH ITGB1 AND ITGB1BP1, AND MUTAGENESIS OF ASN-192
RP   AND TYR-195.
RX   PubMed=11741838; DOI=10.1093/hmg/10.25.2953;
RA   Zhang J., Clatterbuck R.E., Rigamonti D., Chang D.D., Dietz H.C.;
RT   "Interaction between krit1 and icap1alpha infers perturbation of integrin
RT   beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous
RT   malformation.";
RL   Hum. Mol. Genet. 10:2953-2960(2001).
RN   [12]
RP   INTERACTION WITH ITGB1BP1, AND MUTAGENESIS OF ASN-192 AND TYR-195.
RX   PubMed=11854171; DOI=10.1093/hmg/11.4.389;
RA   Zawistowski J.S., Serebriiskii I.G., Lee M.F., Golemis E.A., Marchuk D.A.;
RT   "KRIT1 association with the integrin-binding protein ICAP-1: a new
RT   direction in the elucidation of cerebral cavernous malformations (CCM1)
RT   pathogenesis.";
RL   Hum. Mol. Genet. 11:389-396(2002).
RN   [13]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH ITGB1BP1 AND RAP1A, INTERACTION
RP   WITH ITGB1BP1 AND RAP1A, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   47-LYS--LYS-50 AND 192-ASN--TYR-195.
RX   PubMed=17916086; DOI=10.1111/j.1742-4658.2007.06068.x;
RA   Beraud-Dufour S., Gautier R., Albiges-Rizo C., Chardin P., Faurobert E.;
RT   "Krit 1 interactions with microtubules and membranes are regulated by Rap1
RT   and integrin cytoplasmic domain associated protein-1.";
RL   FEBS J. 274:5518-5532(2007).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CDH5.
RX   PubMed=20332120; DOI=10.1242/jcs.059329;
RA   Lampugnani M.G., Orsenigo F., Rudini N., Maddaluno L., Boulday G.,
RA   Chapon F., Dejana E.;
RT   "CCM1 regulates vascular-lumen organization by inducing endothelial
RT   polarity.";
RL   J. Cell Sci. 123:1073-1080(2010).
RN   [15]
RP   FUNCTION.
RX   PubMed=20668652; DOI=10.1371/journal.pone.0011786;
RA   Goitre L., Balzac F., Degani S., Degan P., Marchi S., Pinton P.,
RA   Retta S.F.;
RT   "KRIT1 regulates the homeostasis of intracellular reactive oxygen
RT   species.";
RL   PLoS ONE 5:E11786-E11786(2010).
RN   [16]
RP   FUNCTION.
RX   PubMed=20616044; DOI=10.1073/pnas.1000132107;
RA   Wuestehube J., Bartol A., Liebler S.S., Bruetsch R., Zhu Y., Felbor U.,
RA   Sure U., Augustin H.G., Fischer A.;
RT   "Cerebral cavernous malformation protein CCM1 inhibits sprouting
RT   angiogenesis by activating DELTA-NOTCH signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:12640-12645(2010).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RAP1A, AND MUTAGENESIS OF
RP   ARG-452.
RX   PubMed=21633110; DOI=10.1091/mbc.e11-02-0157;
RA   Liu J.J., Stockton R.A., Gingras A.R., Ablooglu A.J., Han J., Bobkov A.A.,
RA   Ginsberg M.H.;
RT   "A mechanism of Rap1-induced stabilization of endothelial cell--cell
RT   junctions.";
RL   Mol. Biol. Cell 22:2509-2519(2011).
RN   [18]
RP   FUNCTION.
RX   PubMed=26417067; DOI=10.15252/emmm.201505316;
RA   Marchi S., Corricelli M., Trapani E., Bravi L., Pittaro A.,
RA   Delle Monache S., Ferroni L., Patergnani S., Missiroli S., Goitre L.,
RA   Trabalzini L., Rimessi A., Giorgi C., Zavan B., Cassoni P., Dejana E.,
RA   Retta S.F., Pinton P.;
RT   "Defective autophagy is a key feature of cerebral cavernous
RT   malformations.";
RL   EMBO Mol. Med. 7:1403-1417(2015).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 420-736 IN COMPLEX WITH RAP1B,
RP   MUTAGENESIS OF SER-430; ARG-432 AND ARG-452, AND INTERACTION WITH RAP1B.
RX   PubMed=22577140; DOI=10.1074/jbc.m112.361295;
RA   Li X., Zhang R., Draheim K.M., Liu W., Calderwood D.A., Boggon T.J.;
RT   "Structural basis for small G protein effector interaction of Ras-related
RT   protein 1 (Rap1) and adaptor protein Krev interaction trapped 1 (KRIT1).";
RL   J. Biol. Chem. 287:22317-22327(2012).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) OF 417-736 IN COMPLEX WITH HEG1,
RP   INTERACTION WITH HEG1; RAP1A AND CCM2, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF LEU-717 AND LEU-721.
RX   PubMed=23007647; DOI=10.1083/jcb.201205109;
RA   Gingras A.R., Liu J.J., Ginsberg M.H.;
RT   "Structural basis of the junctional anchorage of the cerebral cavernous
RT   malformations complex.";
RL   J. Cell Biol. 199:39-48(2012).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.54 ANGSTROMS) OF 1-198 IN COMPLEX WITH ITGB1BP1,
RP   INTERACTION WITH ITGB1BP1, FUNCTION, DOMAIN, AND MUTAGENESIS OF ALA-176;
RP   ARG-179; PRO-182; ARG-185; ASN-192 AND TYR-195.
RX   PubMed=23317506; DOI=10.1016/j.molcel.2012.12.005;
RA   Liu W., Draheim K.M., Zhang R., Calderwood D.A., Boggon T.J.;
RT   "Mechanism for KRIT1 release of ICAP1-mediated suppression of integrin
RT   activation.";
RL   Mol. Cell 49:719-729(2013).
RN   [22] {ECO:0007744|PDB:5D68}
RP   X-RAY CRYSTALLOGRAPHY (2.91 ANGSTROMS) OF 259-736, AND ANK REPEAT DOMAIN.
RX   PubMed=26458359; DOI=10.1016/j.jsb.2015.10.006;
RA   Zhang R., Li X., Boggon T.J.;
RT   "Structural analysis of the KRIT1 ankyrin repeat and FERM domains reveals a
RT   conformationally stable ARD-FERM interface.";
RL   J. Struct. Biol. 192:449-456(2015).
CC   -!- FUNCTION: Component of the CCM signaling pathway which is a crucial
CC       regulator of heart and vessel formation and integrity (By similarity).
CC       Negative regulator of angiogenesis. Inhibits endothelial proliferation,
CC       apoptosis, migration, lumen formation and sprouting angiogenesis in
CC       primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-
CC       dependent and independent manner, and inhibits ERK1/2 phosphorylation
CC       indirectly through activation of the DELTA-NOTCH cascade. Acts in
CC       concert with CDH5 to establish and maintain correct endothelial cell
CC       polarity and vascular lumen and these effects are mediated by
CC       recruitment and activation of the Par polarity complex and RAP1B.
CC       Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and
CC       RAP1B to the cell junction, and cell junction stabilization. Plays a
CC       role in integrin signaling via its interaction with ITGB1BP1; this
CC       prevents the interaction between ITGB1 and ITGB1BP1. Microtubule-
CC       associated protein that binds to phosphatidylinositol 4,5-bisphosphate
CC       (PIP2)-containing membranes in a GTP-bound RAP1-dependent manner. Plays
CC       an important role in the maintenance of the intracellular reactive
CC       oxygen species (ROS) homeostasis to prevent oxidative cellular damage.
CC       Regulates the homeostasis of intracellular ROS through an antioxidant
CC       pathway involving FOXO1 and SOD2. Facilitates the down-regulation of
CC       cyclin-D1 (CCND1) levels required for cell transition from
CC       proliferative growth to quiescence by preventing the accumulation of
CC       intracellular ROS through the modulation of FOXO1 and SOD2 levels. May
CC       play a role in the regulation of macroautophagy through the down-
CC       regulation of the mTOR pathway (PubMed:26417067).
CC       {ECO:0000250|UniProtKB:Q6S5J6, ECO:0000269|PubMed:11741838,
CC       ECO:0000269|PubMed:17916086, ECO:0000269|PubMed:20332120,
CC       ECO:0000269|PubMed:20616044, ECO:0000269|PubMed:20668652,
CC       ECO:0000269|PubMed:21633110, ECO:0000269|PubMed:23317506,
CC       ECO:0000269|PubMed:26417067}.
CC   -!- SUBUNIT: Interacts with CDH5 (PubMed:20332120). Found in a complex, at
CC       least composed of ITGB1BP1, KRIT1 and RAP1A. Interacts (via C-terminus
CC       FERM domain) with RAP1A (active GTP-bound form preferentially); the
CC       interaction does not induce the opening conformation of KRIT1.
CC       Interacts (via FERM domain) with RAP1B. Interacts (via N-terminus NPXY
CC       motif) with ITGB1BP1; the interaction induces the opening conformation
CC       of KRIT1 and competes with ITGB1 for ITGB1BP1 interaction. Interacts
CC       with HEG1 and CCM2; greatly facilitates CCM2-binding to HEG1.
CC       Associates (via N-terminus and C-terminus regions) with microtubules;
CC       the interaction is inhibited in presence of ITGB1BP1 and active GTP-
CC       bound RAP1A. {ECO:0000269|PubMed:11741838, ECO:0000269|PubMed:11854171,
CC       ECO:0000269|PubMed:17916086, ECO:0000269|PubMed:20332120,
CC       ECO:0000269|PubMed:21633110, ECO:0000269|PubMed:22577140,
CC       ECO:0000269|PubMed:23007647, ECO:0000269|PubMed:23317506,
CC       ECO:0000269|PubMed:9285558}.
CC   -!- INTERACTION:
CC       O00522; Q9BSQ5: CCM2; NbExp=15; IntAct=EBI-1573121, EBI-1573056;
CC       O00522; Q9BSQ5-1: CCM2; NbExp=2; IntAct=EBI-1573121, EBI-16157769;
CC       O00522; Q9ULI3: HEG1; NbExp=5; IntAct=EBI-1573121, EBI-12734419;
CC       O00522; O14713: ITGB1BP1; NbExp=4; IntAct=EBI-1573121, EBI-2127319;
CC       O00522; P61086: UBE2K; NbExp=3; IntAct=EBI-1573121, EBI-473850;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton. Cell membrane;
CC       Peripheral membrane protein. Cell junction. Note=KRIT1 and CDH5
CC       reciprocally regulate their localization to endothelial cell-cell
CC       junctions. Association with RAP1 relocalizes KRIT1 from microtubules to
CC       cell junction membranes. Translocates from the cytoplasm along
CC       microtubules to the cell membrane in a ITGB1BP1-dependent manner.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O00522-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00522-2; Sequence=VSP_015800;
CC       Name=3;
CC         IsoId=O00522-3; Sequence=VSP_043327;
CC   -!- TISSUE SPECIFICITY: Low levels in brain. Very weak expression found in
CC       heart and muscle. {ECO:0000269|PubMed:9285558}.
CC   -!- DOMAIN: The FERM domain mediates binding to RAP1A and RAP1B and is
CC       necessary for binding to phosphatidylinositol 4,5-bisphosphate (PIP2).
CC       {ECO:0000269|PubMed:23317506}.
CC   -!- DOMAIN: The N-terminal domain has structural similarity to the nudix
CC       hydrolase domain, despite the absence of a nudix box and low sequence
CC       similarity with nudix hydrolase domains. The N-terminus and the C-
CC       terminus part associate together via the NPAY binding motif and adopt a
CC       lose conformation that is disrupted by ITGB1BP1, but not by RAP1A.
CC       {ECO:0000269|PubMed:23317506}.
CC   -!- DOMAIN: Contains 4 ANK repeats that precede the FERM domain.
CC       {ECO:0000269|PubMed:26458359}.
CC   -!- DISEASE: Cerebral cavernous malformations 1 (CCM1) [MIM:116860]: A form
CC       of cerebral cavernous malformations, a congenital vascular anomaly of
CC       the central nervous system that can result in hemorrhagic stroke,
CC       seizures, recurrent headaches, and focal neurologic deficits. The
CC       lesions are characterized by grossly enlarged blood vessels consisting
CC       of a single layer of endothelium and without any intervening neural
CC       tissue, ranging in diameter from a few millimeters to several
CC       centimeters. CCM1 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:12172908}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U90268; AAB58582.1; -; mRNA.
DR   EMBL; U90269; AAC01535.1; -; Genomic_DNA.
DR   EMBL; AF310133; AAG47774.1; -; mRNA.
DR   EMBL; AF296765; AAG10220.2; -; mRNA.
DR   EMBL; AF388384; AAM19465.1; -; mRNA.
DR   EMBL; AY380057; AAQ94072.1; -; mRNA.
DR   EMBL; AK055305; BAG51497.1; -; mRNA.
DR   EMBL; AC000120; AAS07420.1; -; Genomic_DNA.
DR   EMBL; BC094684; AAH94684.1; -; mRNA.
DR   EMBL; BC098442; AAH98442.1; -; mRNA.
DR   EMBL; AJ294850; CAC17608.1; -; mRNA.
DR   EMBL; AY993945; AAY25568.1; -; Genomic_DNA.
DR   CCDS; CCDS34679.1; -. [O00522-3]
DR   CCDS; CCDS5624.1; -. [O00522-1]
DR   RefSeq; NP_001013424.1; NM_001013406.1. [O00522-3]
DR   RefSeq; NP_004903.2; NM_004912.3. [O00522-1]
DR   RefSeq; NP_919436.1; NM_194454.1. [O00522-1]
DR   RefSeq; NP_919437.1; NM_194455.1. [O00522-1]
DR   RefSeq; NP_919438.1; NM_194456.1. [O00522-1]
DR   RefSeq; XP_005250717.1; XM_005250660.3.
DR   RefSeq; XP_005250719.1; XM_005250662.3.
DR   RefSeq; XP_005250722.1; XM_005250665.3.
DR   RefSeq; XP_005250723.1; XM_005250666.3.
DR   RefSeq; XP_005250724.1; XM_005250667.2.
DR   RefSeq; XP_005250725.1; XM_005250668.3.
DR   RefSeq; XP_005250726.1; XM_005250669.3.
DR   RefSeq; XP_006716224.1; XM_006716161.3.
DR   RefSeq; XP_006716225.1; XM_006716162.3.
DR   RefSeq; XP_006716226.1; XM_006716163.3.
DR   RefSeq; XP_011514953.1; XM_011516651.2.
DR   RefSeq; XP_011514955.1; XM_011516653.2.
DR   RefSeq; XP_011514956.1; XM_011516654.2.
DR   RefSeq; XP_011514957.1; XM_011516655.2.
DR   RefSeq; XP_011514958.1; XM_011516656.2.
DR   RefSeq; XP_011514959.1; XM_011516657.2.
DR   RefSeq; XP_011514960.1; XM_011516658.2.
DR   RefSeq; XP_011514961.1; XM_011516659.2.
DR   RefSeq; XP_011514962.1; XM_011516660.2.
DR   RefSeq; XP_011514963.1; XM_011516661.2.
DR   RefSeq; XP_016868244.1; XM_017012755.1.
DR   RefSeq; XP_016868245.1; XM_017012756.1.
DR   RefSeq; XP_016868246.1; XM_017012757.1.
DR   PDB; 3U7D; X-ray; 2.49 A; A/C=417-736.
DR   PDB; 4DX8; X-ray; 2.54 A; H/I/J/K=1-198.
DR   PDB; 4DXA; X-ray; 1.95 A; B=420-736.
DR   PDB; 4HDO; X-ray; 1.67 A; A=417-736.
DR   PDB; 4HDQ; X-ray; 1.95 A; A=417-736.
DR   PDB; 4JIF; X-ray; 1.70 A; B=170-198.
DR   PDB; 4TKN; X-ray; 3.00 A; D/E/F=225-237.
DR   PDB; 5D68; X-ray; 2.91 A; A/B/C=259-736.
DR   PDB; 6OQ3; X-ray; 1.85 A; A=417-736.
DR   PDB; 6OQ4; X-ray; 1.75 A; A=417-736.
DR   PDB; 6UZK; X-ray; 1.92 A; A=417-736.
DR   PDBsum; 3U7D; -.
DR   PDBsum; 4DX8; -.
DR   PDBsum; 4DXA; -.
DR   PDBsum; 4HDO; -.
DR   PDBsum; 4HDQ; -.
DR   PDBsum; 4JIF; -.
DR   PDBsum; 4TKN; -.
DR   PDBsum; 5D68; -.
DR   PDBsum; 6OQ3; -.
DR   PDBsum; 6OQ4; -.
DR   PDBsum; 6UZK; -.
DR   AlphaFoldDB; O00522; -.
DR   SMR; O00522; -.
DR   BioGRID; 107330; 47.
DR   ComplexPortal; CPX-983; ICAP1-KRIT1 integrin activation complex.
DR   ComplexPortal; CPX-984; CCM endothelial permeability complex.
DR   CORUM; O00522; -.
DR   DIP; DIP-40610N; -.
DR   IntAct; O00522; 10.
DR   STRING; 9606.ENSP00000378015; -.
DR   iPTMnet; O00522; -.
DR   PhosphoSitePlus; O00522; -.
DR   BioMuta; KRIT1; -.
DR   EPD; O00522; -.
DR   jPOST; O00522; -.
DR   MassIVE; O00522; -.
DR   MaxQB; O00522; -.
DR   PaxDb; O00522; -.
DR   PeptideAtlas; O00522; -.
DR   ProteomicsDB; 47953; -. [O00522-1]
DR   ProteomicsDB; 47954; -. [O00522-2]
DR   ProteomicsDB; 47955; -. [O00522-3]
DR   Antibodypedia; 15587; 213 antibodies from 27 providers.
DR   DNASU; 889; -.
DR   Ensembl; ENST00000340022.6; ENSP00000344668.2; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000394503.6; ENSP00000378011.2; ENSG00000001631.17. [O00522-3]
DR   Ensembl; ENST00000394505.7; ENSP00000378013.2; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000394507.5; ENSP00000378015.1; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000412043.6; ENSP00000410909.2; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000425073.2; ENSP00000404790.2; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000444960.6; ENSP00000388076.2; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000458177.7; ENSP00000391675.2; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000686094.1; ENSP00000510015.1; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000686527.1; ENSP00000509139.1; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000687135.1; ENSP00000509617.1; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000688404.1; ENSP00000509939.1; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000688665.1; ENSP00000509209.1; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000689556.1; ENSP00000508543.1; ENSG00000001631.17. [O00522-3]
DR   Ensembl; ENST00000690529.1; ENSP00000510733.1; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000690720.1; ENSP00000509832.1; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000690908.1; ENSP00000510110.1; ENSG00000001631.17. [O00522-3]
DR   Ensembl; ENST00000692157.1; ENSP00000509514.1; ENSG00000001631.17. [O00522-1]
DR   Ensembl; ENST00000692807.1; ENSP00000508564.1; ENSG00000001631.17. [O00522-1]
DR   GeneID; 889; -.
DR   KEGG; hsa:889; -.
DR   MANE-Select; ENST00000394505.7; ENSP00000378013.2; NM_194454.3; NP_919436.1.
DR   UCSC; uc003ulr.2; human. [O00522-1]
DR   AGR; HGNC:1573; -.
DR   CTD; 889; -.
DR   DisGeNET; 889; -.
DR   GeneCards; KRIT1; -.
DR   GeneReviews; KRIT1; -.
DR   HGNC; HGNC:1573; KRIT1.
DR   HPA; ENSG00000001631; Low tissue specificity.
DR   MalaCards; KRIT1; -.
DR   MIM; 116860; phenotype.
DR   MIM; 604214; gene.
DR   neXtProt; NX_O00522; -.
DR   OpenTargets; ENSG00000001631; -.
DR   Orphanet; 221061; Familial cerebral cavernous malformation.
DR   PharmGKB; PA26144; -.
DR   VEuPathDB; HostDB:ENSG00000001631; -.
DR   eggNOG; KOG4335; Eukaryota.
DR   GeneTree; ENSGT00530000063721; -.
DR   HOGENOM; CLU_022188_0_0_1; -.
DR   InParanoid; O00522; -.
DR   OMA; INIQLNC; -.
DR   OrthoDB; 2876335at2759; -.
DR   PhylomeDB; O00522; -.
DR   TreeFam; TF317921; -.
DR   BioCyc; MetaCyc:ENSG00000001631-MON; -.
DR   PathwayCommons; O00522; -.
DR   SignaLink; O00522; -.
DR   BioGRID-ORCS; 889; 14 hits in 1164 CRISPR screens.
DR   ChiTaRS; KRIT1; human.
DR   GeneWiki; KRIT1; -.
DR   GenomeRNAi; 889; -.
DR   Pharos; O00522; Tbio.
DR   PRO; PR:O00522; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; O00522; protein.
DR   Bgee; ENSG00000001631; Expressed in calcaneal tendon and 106 other tissues.
DR   ExpressionAtlas; O00522; baseline and differential.
DR   Genevisible; O00522; HS.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-KW.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0030695; F:GTPase regulator activity; TAS:ProtInc.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0045454; P:cell redox homeostasis; IMP:UniProtKB.
DR   GO; GO:0003158; P:endothelium development; NAS:ComplexPortal.
DR   GO; GO:0033622; P:integrin activation; IDA:ComplexPortal.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0010596; P:negative regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0032092; P:positive regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0045765; P:regulation of angiogenesis; NAS:ComplexPortal.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; IMP:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:ProtInc.
DR   CDD; cd14473; FERM_B-lobe; 1.
DR   CDD; cd13197; FERM_C_CCM1; 1.
DR   DisProt; DP01333; -.
DR   Gene3D; 1.20.80.10; -; 1.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR   Gene3D; 3.30.70.2240; KRIT, N-terminal Nudix domain, NPxY motif-rich region; 2.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_sf.
DR   InterPro; IPR035963; FERM_2.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR041791; KRIT1_FERM_C.
DR   InterPro; IPR032022; NUDIX.
DR   InterPro; IPR043058; NUDIX_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   PANTHER; PTHR13283; KREV INTERACTION TRAPPED 1-RELATED; 1.
DR   PANTHER; PTHR13283:SF11; KREV INTERACTION TRAPPED PROTEIN 1; 1.
DR   Pfam; PF13857; Ank_5; 1.
DR   Pfam; PF00373; FERM_M; 1.
DR   Pfam; PF16705; NUDIX_5; 1.
DR   SMART; SM00248; ANK; 3.
DR   SMART; SM00295; B41; 1.
DR   SUPFAM; SSF48403; Ankyrin repeat; 1.
DR   SUPFAM; SSF47031; Second domain of FERM; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 1.
DR   PROSITE; PS50057; FERM_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ANK repeat;
KW   Cell junction; Cell membrane; Cytoplasm; Cytoskeleton; Disease variant;
KW   Membrane; Reference proteome; Repeat.
FT   CHAIN           1..736
FT                   /note="Krev interaction trapped protein 1"
FT                   /id="PRO_0000067023"
FT   REPEAT          287..316
FT                   /note="ANK 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          320..350
FT                   /note="ANK 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          354..383
FT                   /note="ANK 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          388..419
FT                   /note="ANK 4"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          420..734
FT                   /note="FERM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00084"
FT   REGION          1..170
FT                   /note="N-terminal domain similar to Nudix hydrolase domain"
FT   REGION          172..195
FT                   /note="Interaction with ITGB1BP1"
FT   REGION          430..452
FT                   /note="Interaction with RAP1B"
FT                   /evidence="ECO:0000269|PubMed:22577140"
FT   VAR_SEQ         1..207
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9285558"
FT                   /id="VSP_015800"
FT   VAR_SEQ         283..330
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043327"
FT   VARIANT         97
FT                   /note="F -> S (in CCM1)"
FT                   /evidence="ECO:0000269|PubMed:12172908"
FT                   /id="VAR_023573"
FT   VARIANT         569
FT                   /note="K -> E (in CCM1)"
FT                   /evidence="ECO:0000269|PubMed:12172908"
FT                   /id="VAR_023574"
FT   MUTAGEN         47..50
FT                   /note="KKRK->AAAA: Reduces interaction with microtubules,
FT                   but not with ITGB1BP1."
FT                   /evidence="ECO:0000269|PubMed:17916086"
FT   MUTAGEN         176
FT                   /note="A->D: Strongly reduces ITGB1BP1 binding; when
FT                   associated with D-182."
FT                   /evidence="ECO:0000269|PubMed:23317506"
FT   MUTAGEN         179
FT                   /note="R->A: Strongly reduces ITGB1BP1 binding; when
FT                   associated with A-179."
FT                   /evidence="ECO:0000269|PubMed:23317506"
FT   MUTAGEN         182
FT                   /note="P->D: Strongly reduces ITGB1BP1 binding; when
FT                   associated with D-176."
FT                   /evidence="ECO:0000269|PubMed:23317506"
FT   MUTAGEN         185
FT                   /note="R->A: Strongly reduces ITGB1BP1 binding; when
FT                   associated with A-179."
FT                   /evidence="ECO:0000269|PubMed:23317506"
FT   MUTAGEN         192..195
FT                   /note="NPAY->APAA: Reduces interaction with ITGB1BP1."
FT                   /evidence="ECO:0000269|PubMed:17916086"
FT   MUTAGEN         192
FT                   /note="N->A: Reduces ITGB1BP1 binding; when associated with
FT                   A-195."
FT                   /evidence="ECO:0000269|PubMed:11741838,
FT                   ECO:0000269|PubMed:11854171, ECO:0000269|PubMed:23317506"
FT   MUTAGEN         195
FT                   /note="Y->A: Reduces ITGB1BP1 binding; when associated with
FT                   A-192."
FT                   /evidence="ECO:0000269|PubMed:11741838,
FT                   ECO:0000269|PubMed:11854171, ECO:0000269|PubMed:23317506"
FT   MUTAGEN         430
FT                   /note="S->E: Impairs interaction with RAP1B."
FT                   /evidence="ECO:0000269|PubMed:22577140"
FT   MUTAGEN         432
FT                   /note="R->E: Impairs interaction with RAP1B."
FT                   /evidence="ECO:0000269|PubMed:22577140"
FT   MUTAGEN         452
FT                   /note="R->E: 40-fold-reduced affinity for Rap1A."
FT                   /evidence="ECO:0000269|PubMed:21633110,
FT                   ECO:0000269|PubMed:22577140"
FT   MUTAGEN         452
FT                   /note="R->E: Impairs interaction with RAP1B."
FT                   /evidence="ECO:0000269|PubMed:21633110,
FT                   ECO:0000269|PubMed:22577140"
FT   MUTAGEN         717
FT                   /note="L->A: Strongly reduced affinity for HEG1; when
FT                   associated with A-721."
FT                   /evidence="ECO:0000269|PubMed:23007647"
FT   MUTAGEN         721
FT                   /note="L->A: Strongly reduced affinity for HEG1; when
FT                   associated with A-717."
FT                   /evidence="ECO:0000269|PubMed:23007647"
FT   CONFLICT        138
FT                   /note="I -> T (in Ref. 5; AAQ94072)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        234
FT                   /note="F -> G (in Ref. 1; AAB58582)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        731
FT                   /note="P -> A (in Ref. 1; AAB58582, 2; AAG47774 and 5;
FT                   AAQ94072)"
FT                   /evidence="ECO:0000305"
FT   STRAND          9..17
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   HELIX           30..32
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   STRAND          33..39
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   STRAND          54..57
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   HELIX           64..75
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   STRAND          92..98
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   STRAND          107..114
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   STRAND          131..134
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   HELIX           135..141
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   HELIX           151..170
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   HELIX           173..178
FT                   /evidence="ECO:0007829|PDB:4DX8"
FT   HELIX           182..185
FT                   /evidence="ECO:0007829|PDB:4JIF"
FT   STRAND          186..191
FT                   /evidence="ECO:0007829|PDB:4JIF"
FT   HELIX           193..195
FT                   /evidence="ECO:0007829|PDB:4JIF"
FT   TURN            232..235
FT                   /evidence="ECO:0007829|PDB:4TKN"
FT   HELIX           291..297
FT                   /evidence="ECO:0007829|PDB:5D68"
FT   HELIX           301..309
FT                   /evidence="ECO:0007829|PDB:5D68"
FT   HELIX           324..330
FT                   /evidence="ECO:0007829|PDB:5D68"
FT   HELIX           334..342
FT                   /evidence="ECO:0007829|PDB:5D68"
FT   HELIX           358..364
FT                   /evidence="ECO:0007829|PDB:5D68"
FT   HELIX           368..376
FT                   /evidence="ECO:0007829|PDB:5D68"
FT   HELIX           392..399
FT                   /evidence="ECO:0007829|PDB:5D68"
FT   HELIX           404..412
FT                   /evidence="ECO:0007829|PDB:5D68"
FT   STRAND          415..417
FT                   /evidence="ECO:0007829|PDB:5D68"
FT   STRAND          421..425
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          431..435
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           439..441
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           444..449
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           455..458
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          461..467
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          470..473
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           480..485
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           487..494
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           499..501
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          505..510
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           516..519
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           525..541
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           548..563
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           568..571
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          572..574
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           578..581
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   TURN            582..584
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           587..589
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   TURN            590..593
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           594..596
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           598..610
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          612..614
FT                   /evidence="ECO:0007829|PDB:6UZK"
FT   HELIX           618..629
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   TURN            633..636
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          638..645
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   TURN            650..652
FT                   /evidence="ECO:0007829|PDB:4HDQ"
FT   STRAND          655..662
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          664..671
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   TURN            672..674
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          677..682
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          685..690
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          694..701
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   TURN            702..705
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   STRAND          706..711
FT                   /evidence="ECO:0007829|PDB:4HDO"
FT   HELIX           715..728
FT                   /evidence="ECO:0007829|PDB:4HDO"
SQ   SEQUENCE   736 AA;  84348 MW;  D11F75ED629E85AC CRC64;
     MGNPENIEDA YVAVIRPKNT ASLNSREYRA KSYEILLHEV PIEGQKKKRK KVLLETKLQG
     NSEITQGILD YVVETTKPIS PANQGIRGKR VVLMKKFPLD GEKMGREASL FIVPSVVKDN
     TKYTYTPGCP IFYCLQDIMR VCSESSTHFA TLTARMLIAL DKWLDERHAQ SHFIPALFRP
     SPLERIKTNV INPAYATESG QTENSLHMGY SALEIKSKML ALEKADTCIY NPLFGSDLQY
     TNRVDKVVIN PYFGLGAPDY SKIQIPKQEK WQRSMSSVTE DKERQWVDDF PLHRSACEGD
     SELLSRLLSE RFSVNQLDSD HWAPIHYACW YGKVEATRIL LEKGKCNPNL LNGQLSSPLH
     FAAGGGHAEI VQILLNHPET DRHITDQQGR SPLNICEENK QNNWEEAAKL LKEAINKPYE
     KVRIYRMDGS YRSVELKHGN NTTVQQIMEG MRLSQETQQY FTIWICSENL SLQLKPYHKP
     LQHVRDWPEI LAELTNLDPQ RETPQLFLRR DVRLPLEVEK QIEDPLAILI LFDEARYNLL
     KGFYTAPDAK LITLASLLLQ IVYGNYESKK HKQGFLNEEN LKSIVPVTKL KSKAPHWTNR
     ILHEYKNLST SEGVSKEMHH LQRMFLQNCW EIPTYGAAFF TGQIFTKASP SNHKVIPVYV
     GVNIKGLHLL NMETKALLIS LKYGCFMWQL GDTDTCFQIH SMENKMSFIV HTKQAGLVVK
     LLMKLNGQLM PTERNS
//
